stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.41
0.51
+3.67%
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) Total debt
Biohaven Ltd.'s total debt at the end of fiscal 2025 was $238.9M, up 681.2% from $30.6M in fiscal 2022. At the end of the quarter to 30 September 2026 it was $264.3M. Over the past ten years it has ranged from $595.0K (fiscal 2016) to $267.5M (fiscal 2020); the current reading is higher than 71% of that period. Biohaven Ltd. ranks 45th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $238.9M | 681.20% |
| FY2022 | $30.6M | 993.35% |
| FY2021 | $2.8M | (98.95%) |
| FY2020 | $267.5M | 7.85% |
| FY2019 | $248.0M | 110.17% |
| FY2018 | $118.0M | 19,731.93% |
| FY2016 | $595.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $264.3M | 1.86% |
| Jun 2026 | $259.5M | 7.26% |
| Mar 2026 | $241.9M | 1.26% |
| Dec 2025 | $238.9M | (10.95%) |
| 20 more quarters | Free account |
Against its own ten years
Low $595.0K
High $267.5M
Ten-year median
$118.0M
Current reading's percentile
71
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. | $264.3M |
| ADMA ADMA Biologics Inc compare | $198.9M |
| VCEL Vericel Corporation compare | $85.1M |
| VERA Vera Therapeutics, Inc. compare | $75.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $39.0M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $5.5M |
| CLDX Celldex Therapeutics, Inc. compare | $1.2M |
| IMNM Immunome, Inc. compare | $228.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt